These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19221109)

  • 1. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy.
    Eckstein AK; Lösch C; Glowacka D; Schott M; Mann K; Esser J; Morgenthaler NG
    Br J Ophthalmol; 2009 Aug; 93(8):1052-6. PubMed ID: 19221109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy.
    Ponto KA; Binder H; Diana T; Matheis N; Otto AF; Pitz S; Pfeiffer N; Kahaly GJ
    Thyroid; 2015 Aug; 25(8):942-8. PubMed ID: 26244413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSH receptor antibodies in autoimmune thyroiditis.
    Nordmeyer JP; Hashim FA; Shafeh T; Eickenbusch W; Rees Smith B
    J Clin Lab Immunol; 1988 May; 26(1):21-4. PubMed ID: 3184158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associated ophthalmopathy and proptosis.
    Kvetny J; Puhakka KB; Røhl L
    Acta Ophthalmol Scand; 2006 Jun; 84(3):419-23. PubMed ID: 16704711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
    Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
    Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Graves' ophthalmopathy may be a risk factor for the development of postthyroidectomy hypocalcaemia.
    Hassan I; Danila R; Maurer E; Osei-Agymang T; Zielke A
    Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):614-8. PubMed ID: 18523918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.
    Leo M; Menconi F; Rocchi R; Latrofa F; Sisti E; Profilo MA; Mazzi B; Albano E; Nardi M; Vitti P; Marcocci C; Marinò M
    Thyroid; 2015 Mar; 25(3):347-51. PubMed ID: 25584927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.
    Eckstein A; Esser J; Mann K; Schott M
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():198-203. PubMed ID: 20467363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcome of surgical treatment for Graves's disease and a correlation between its clinical course and values of TSH receptor antibodies (TRAb)].
    Sugino K; Mimura T; Toshima K; Ozaki O; Ito K
    Nihon Geka Gakkai Zasshi; 1993 Jun; 94(6):611-4. PubMed ID: 8341243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid volume and severity of Graves' orbitopathy.
    Profilo MA; Sisti E; Marcocci C; Vitti P; Pinchera A; Nardi M; Rocchi R; Latrofa F; Menconi F; Altea MA; Leo M; Rago T; Marinò M
    Thyroid; 2013 Jan; 23(1):97-102. PubMed ID: 23088654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
    Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy.
    Hiromatsu Y; Eguchi H; Matsuo Y; Kato T; Tani J; Watanabe S; Teshima Y; Araki N
    Endocr J; 2020 Mar; 67(3):347-352. PubMed ID: 31827052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age influences the severity of Graves' ophthalmopathy.
    Lin MC; Hsu FM; Bee YS; Ger LP
    Kaohsiung J Med Sci; 2008 Jun; 24(6):283-8. PubMed ID: 18635413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
    Liu C; Hermsen D; Domberg J; Graeber C; Hautzel H; Duan Y; Xu KF; Liu CP; Mao XD; Cupisti K; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Jul; 40(7):479-83. PubMed ID: 18504673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.